28 September 2023
28 September 2023
The drug, acquired in 2020 as part of a $4.9b deal, is ‘unlikely to demonstrate survival benefit compared to standard of care’ in acute myeloid leukaemia.
As part of the BARDA contract, Gritstone bio will launch a Phase IIb vaccine trial enrolling 10,000 subjects.
The procedure is part of a clinical study supported by the European Innovation Council, investigating the therapy’s safety and effectiveness.
A wide-ranging portfolio of therapeutic fields will be part of the new alliance.
The alliance will aid diverse and medically underserved rural communities to gain equitable access to healthcare.
A District Judge overturned last year's jury verdict, declaring the application of Teva's patents overly broad.
The company has fully enrolled the fourth cohort of the monotherapy arm at a dose of 10mg/kg.
The study will assess the usability of the PressureSafe device to detect pressure injuries in people with darker skin tones.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
